Category: Uncategorised

Neuromod featured in September’s issue of MedTech Strategist. The article features in the issues “Start ups to watch” section.

Read the full article here : (link: https://www.neuromoddevices.com/content/2-newsroom/20180926-2018/1-neuromod-in-medtech-strategist-14-09-18/neuromod-mts-9-14-18-store-ul.pdf?1537955861 text: MedTech Strategist Article)

Dublin, Ireland, for release on Wednesday, June 26th 2018.

Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specialising in non-invasive neuromodulation technologies, is pleased to announce that Mr. Christopher M. Smith is a Strategic Advisor to the Board as of June 1st, 2018 and will join the company’s Board of Directors from January 3rd, 2019.

Mr. Smith comes to Neuromod’s board with an exemplary track record of leadership in the hearing and medical devices sectors. In January 2018, after 14 years with the company, Mr. Smith retired from his role as Chief Executive Officer and Director of Cochlear Ltd (COH.ASX), the global leader in cochlear implantation technology. During his time at the helm of Cochlear, Mr. Smith oversaw a period of substantial growth reaching annual sales in excess of AUD 1 billion dollars and the market cap of the company grow to AUD 10 billion (USD 7.5 billion).

Dr. Manus Rogan, Chair of the board of Neuromod commented, “We are delighted to welcome Chris to the Company. Neuromod will benefit from his track record guiding companies through rapid growth in the medical device and hearing sectors.”

Prior to Cochlear, Mr. Smith held roles as CEO in Residence with Warburg Pincus and as Group President of Gyrus Group in Reading, England, a market leader in surgical products. Mr Smith has previously served on the board of directors of publicly-listed Xtent Inc. as well as Startek Inc, Universal Biosensors, Gyrus Group Plc, and notably Acclarent Inc., a private ENT-focused medical device company that was acquired by Johnson & Johnson. Mr. Smith holds a BS from Texas A&M University.

Welcoming the appointment, Dr. Ross O’Neill, CEO of Neuromod said: “Chris is a recognised global leader in the hearing industry who is joining us at an exciting point in Neuromod’s evolution. We expect to conclude the second phase of the TENT-A clinical trial later this year and are excited to convert the promise of clinical data into a meaningful therapeutic option for the many patients with tinnitus anxiously awaiting effective, safe and convenient treatments. I look forward to working with Chris to bring this important intervention to market”

Mr. Smith responded: “Tinnitus continues to be one of the largest and most poorly served needs in audiology and hearing. Neuromod are taking an innovative, science-driven and rigorous approach to developing a solution to this large problem. I see in Neuromod’s people and innovative approach the potential for transformative patient impact. I am excited to be part of their endeavour.”

About Neuromod Devices Limited

Neuromod, headquartered in the Digital Hub, Dublin, Ireland, is an emerging medical technology company, specialising in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The company was founded in 2010, by Dr. Ross O’Neill, as a spin-out from Maynooth University.

The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod is conducting extensive clinical trials to confirm the efficacy of its non-invasive neuromodulation platform in this common disorder for which no standard of care has yet been established. Tinnitus affects between 10 and 15% of the global population, and the lives of at least 1 in every 100 people worldwide are severely compromised because of the incessant nature of the illusory sound that is often described as a ringing or buzzing in the ears.

www.NeuromodDevices.com

Contact: FTI Consulting | Media Relations
Melanie Farrell, FTI Consulting
neuromod@fticonsulting.com

Neuromod Devices today announced it has successfully secured the CE Mark for a new bimodal neuromodulation device for the treatment of tinnitus.

The certification was awarded by the company’s Notified Body, the British Standards Institute (BSi) and certifies the safety and efficacy of the product and the competency of the manufacturer.

Enterprise Ireland, IMDA and IDA Ireland are delighted to announce Neuromod Devices Ltd as winners of The Emerging Medical Company of the Year 2014 – 2015 at the 8th annual Medical Industry Excellence Awards.

On winning the award Dr. Ross O’Neill, Chief Executive Officer of Neuromod Devices Ltd expressed his appreciation “It is an honour to be awarded the Emerging Company of the Year by the IMDA, especially in Ireland where we have such a thriving medical technology sector which employs 25,000 people nationwide and accounts for €8bn in exports. We appreciate the ongoing support of IMDA, IBEC and agencies like Enterprise Ireland which enable global innovation in Ireland and help to position Irish companies like Neuromod Devices for global success. We are truly honoured.”

Neuromod Devices has raised €655,000 in capital from company management private investors through an Employment and Investment Incentive (EII) tax-relief scheme. The investment will fund the continued expansion of the company as they prepare to obtain further clinical data to secure global regulatory approvals for the company’s neuromodulation technology for tinnitus.

Neuromod Devices is headquartered in NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD). The company anticipates the Irish launch of the mutebutton® system in Dec 2014, ahead of a wider European launch commencing early 2015.

Neuromod Devices (t/a mutebutton limited) is incorporated by company founder and CEO, Dr. Ross O’Neill. An Irish medical device company specialising in neuromodulation technology, the company will work with academic and clinical partners to research and develop ‘mutebutton’, a new multisensory approach to tinnitus treatment.

CEO Ross O’Neill said, “I am excited to announce our plans to research, develop and clinically evaluate ‘mutebutton’, which is a completely new multisensory approach to the treatment of tinnitus. This is the first time that such a multisensory approach has been taken in human clinical research. Building on promising data from earlier studies, we hope to refine the treatment, obtain further clinical evidence and secure regulatory approval for this promising new technology.